J0575 HCPCS Level II code: Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
J0575 is the HCPCS code for “Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
Short description: Bupren/nal over 10mg bupreno
HCPCS · United States
Notes for J0575
As CMS prints them, with any note J0575 takes from the headings above it.
Note
- CMS processing note 0127: PUBLICATION 100.2, CHAPTER 15, 50.1.
Medicare details
The indicators CMS publishes with J0575 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2015
Where J0575 sits
- 1J codesDrugs administered other than orally
- 2Active code J0575Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0575 mean?
J0575 is the HCPCS code for “Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0575?
CMS lists J0575’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0575
All J codesJ0567Injection, cerliponase alfa, 1 mgJ0570Buprenorphine implant, 74.2 mgJ0571Buprenorphine, oral, 1 mgJ0572Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphineJ0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphineJ0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphineJ0576Injection, buprenorphine extended-release (brixadi), 1 mgJ0577Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapyJ0578Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapyJ0582Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mgJ0583Injection, bivalirudin, 1 mgJ0584Injection, burosumab-twza 1 mg